Market Place
Sourcing Support
PLOS ONE Publishes Data on Allarity DRP® Companion Diagnostic for Dovitinib
30 Aug 2023 //
GLOBENEWSWIRE
Allarity Doses First Patient in Ph1b Trial Evaluating Dovitinib and Stenoparib
20 Mar 2023 //
GLOBENEWSWIRE
FDA sinks Allarity’s plans for lead oncology asset
03 Aug 2022 //
FIERCEBIOTECH
Allarity Therapeutics partners with Lonza to manufacture Dovitinib
23 Sep 2021 //
PHARMAFILE
Allarity Presents Dovitinib Survival Data from DRP® Screened RCC Patients
16 Sep 2021 //
GLOBENEWSWIRE
Allarity Therapeutics Receives Acceptance & Review Notification From USFDA
05 Jul 2021 //
GLOBENEWSWIRE
Allarity Therapeutics Provides Update on Dovitinib Program
23 Oct 2020 //
GLOBENEWSWIRE
Press release Oncology Venture acquires full control of Dovitinib program
08 Jun 2020 //
GLOBENEWSWIRE
Dovitinib LiPlaCis data to support FDA breakthrough designation strategy
07 Feb 2019 //
GLOBENEWSWIRE
Novartis farms out rare disease drug to LifeMax Labs
28 Aug 2018 //
FIERCE BIOTECH
Biotech resurrects a long faded Novartis cancer drug star, using a biomarker
11 Apr 2018 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.